ພະຍາດທີ່ຫາຍາກນີ້ສຸມໃສ່ທໍ່ຫຼັກຊັບແມ່ນບໍ່ໄດ້ຮັບການຕີລາຄາ, ນັກວິເຄາະທີ່ລິເລີ່ມການຄຸ້ມຄອງກ່າວວ່າ

• Cantor Fitzgerald ໄດ້ລິເລີ່ມການຄຸ້ມຄອງກ່ຽວກັບການ KemPharm Inc (NASDAQ: KMPH) with an Overweight rating and a ເປົ້າ ໝາຍ ລາຄາ 20 ໂດລາ.

• Per the analyst, KMPH’s products, pipeline, and execution capability are underappreciated. Therefore, upward earnings-estimate revisions and pipeline advancements should drive the stock higher.

• KMPH focuses on the rare central nervous system and related disorders. KMPH’s AZSTARYS is the first and only approved methylphenidate-based drug containing serdexmethylphenidate (SDX) indicated for attention deficit hyperactivity disorder (ADHD).

• The FDA approved the drug in March 2021.

• The company has shifted its pipeline to focus on rare diseases with arimoclomol for NPC (Niemann-Pick disease) and KP1077 for rare sleep disorders.

• Cantor also believes KP1077 could capture a large share of the idiopathic hypersomnia market based on potential clinical differentiation and combination usage.

• Total cash of $107.4 million is expected to runway into 2026.

• ລາຄາປະຕິບັດງານ: KMPH shares are trading up 2.85% at $4.52 on the last check Thursday.

Latest Ratings for KMPH

ວັນທີ່ສະຫມັກ	ບໍລິສັດ	ການປະຕິບັດ	From	To
Jan 2022	HC Wainwright & Co.	ການຍົກລະດັບ	ເປັນກາງ	ຊື້
Apr 2021	HC Wainwright & Co.	ຮັກສາ		ເປັນກາງ
ມີນາ 2021	HC Wainwright & Co.	Downgrades	ຊື້	ເປັນກາງ

View More Analyst Ratings for KMPH

ເບິ່ງຄະແນນການວິເຄາະຫຼ້າສຸດ

ເບິ່ງເພີ່ມເຕີມຈາກ Benzinga

ຢ່າພາດການແຈ້ງເຕືອນແບບສົດໆໃນຫຸ້ນຂອງເຈົ້າ – ເຂົ້າຮ່ວມ Benzinga Pro ສໍາລັບການຟຣີ! ລອງໃຊ້ເຄື່ອງມືທີ່ຈະຊ່ວຍໃຫ້ທ່ານລົງທຶນຢ່າງສະຫຼາດຂຶ້ນ, ໄວຂຶ້ນ, ແລະດີກວ່າ.

©ປີ 2022 Benzinga.com. Benzinga ບໍ່ໃຫ້ ຄຳ ແນະ ນຳ ດ້ານການລົງທືນ. ທິການ.